Healthcare - Press Releases

SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by the environmental non-profit CDP for leadership in corporate transparency and performance on water security, securing a place on the organization's annual "A List"for the second year.

HONG KONG, March 20, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab (AK104), in combination with concurrent chemoradiotherapy (CCRT) for the treatment of locally advanced cervical cancer.

HELSINKI, March 20, 2025 /PRNewswire/ -- Finland leads the world in happiness for the eighth year running, with an average score of 7.7 out of 10. As the capital of happiness, Helsinki shows that the core of happiness hasn't changed - it's simply found new ways to thrive and welcomed new people along the way.

HELSINKI, March 20, 2025 /PRNewswire/ -- Finland leads the world in happiness for the eighth year running, with an average score of 7.7 out of 10. As the capital of happiness, Helsinki shows that the core of happiness hasn't changed - it's simply found new ways to thrive and welcomed new people along the way.

RIYADH, Saudi Arabia, March 20, 2025 /PRNewswire/ -- BristolMyers Squibb, a leading global biopharmaceutical company, has recently appointed Osama Braiwish as its General Manager for Saudi Arabia and Gulf Countries, an affiliate covering Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and Jordan.

FORT LAUDERDALE, Fla., March 20, 2025 /PRNewswire/ -- Discover the groundbreaking work of Starlight Cardiovascular, a company dedicated to creating life-saving technologies for children with congenital heart disease, a condition affecting countless families nationwide.

(PRNewsfoto/Transamerica Institute) Global Coalition on Aging

BASEL, Switzerland, March 20, 2025 /PRNewswire/ -- Versameb AG ("Versameb"), a clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the issuance of the Notice of Allowance of first Composition of Matter patent in China for its innovative signal peptide technology. This achievement represents a significant milestone in Versameb's mission to advance RNA-based therapeutics and expand its intellectual property portfolio globally.

STRASBOURG, France, MONTREAL, BOSTON, March 20, 2025 /PRNewswire/ -- Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing DT-9046, a candidate with game-changingpotentialin multiple inflammatory disease markets, including atopic dermatitis (AD), inflammatory bowel disease (IBD), arthritis but also neuroinflammation including migraine.

NES ZIONA,Israel, March 20, 2025 /PRNewswire/ -- EyeYon Medical, a global leader in innovative corneal implant solutions, is proud to announce that Dr. Ofer Daphna, the inventor of EndoArt, will deliver an invited keynote lecture at the prestigious World Cornea Congress (WCC) 2025 in Washington, D.C., this weekend. Dr. Daphna will present a decade of groundbreaking development behind EndoArt and share insights from the successful treatment of 500 patients, with nearly six (6) years of follow-up data.

NES ZIONA,Israel, March 20, 2025 /PRNewswire/ -- EyeYon Medical, a global leader in innovative corneal implant solutions, is proud to announce that Dr. Ofer Daphna, the inventor of EndoArt, will deliver an invited keynote lecture at the prestigious World Cornea Congress (WCC) 2025 in Washington, D.C., this weekend. Dr. Daphna will present a decade of groundbreaking development behind EndoArt and share insights from the successful treatment of 500 patients, with nearly six (6) years of follow-up data.

NES ZIONA,Isral, 20 mars 2025 /PRNewswire/ -- EyeYon Medical, leader mondial des solutions innovantes d'implants cornens, est fier d'annoncer que le Dr Ofer Daphna, l'inventeur d'EndoArt, sera invit donner une confrence lors du prestigieux Congrs mondial de la corne (WCC) 2025 Washington, D.C., ce week-end. Le Dr Daphna prsentera une dcennie de dveloppement rvolutionnaire derrire EndoArt et partagera ses connaissances sur le traitement russi de 500 patients, avec prs de six (6) ans de donnes de suivi.

NES ZIONA,Israel, 20. Mrz 2025 /PRNewswire/ -- EyeYon Medical, ein weltweit fhrender Anbieter innovativer Hornhautimplantatlsungen, ist stolz darauf, bekannt zu geben, dass Dr. Ofer Daphna, der Erfinder von EndoArt, an diesem Wochenende auf dem angesehenen World Cornea Congress (WCC) 2025 in Washington, D.C., einen eingeladenen Hauptvortrag halten wird. Dr. Daphna wird die bahnbrechende Entwicklung von EndoArt in den letzten zehn Jahren vorstellen und die Erkenntnisse aus der erfolgreichen Behandlung von 500 Patienten mit einer Nachbeobachtungszeit von fast sechs (6) Jahren vorstellen.

HOUSTON, March 20, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro-hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced its CEO, Dr. Tom Vo, will present at the EDPMA Solutions Summit 2025. This event will take place fromMarch 30 to April 2 at The Broadmoor in Colorado Springs, CO.

Company announcementNo. 03/2025

Company announcementNo. 03/2025

OXFORD, England, March 20, 2025 /PRNewswire/ --Infinitopes, a pioneering precision immuno-oncology company, today announced the appointments of Dan Menichella and Jo Brewer, PhD as Non-Executive Directors to its Board as the company prepares to transition into a clinical stage company with lead vaccine candidate, ITOP1,to treat patients with oesophageal cancer.

With the pilot line environment, non-invasive devices enabling early cancer detection and remote heart disease monitoring can advance from research and development to market faster than before, benefiting patients more quickly. Established by VTT with an investment of EUR 3.4 million, the facility is unique in Europe and is focused in particular on medical devices based on photonics technology.

The multiple myeloma market is expected to grow in the upcoming years, owing to a rise in incident cases, label expansion and penetration of current therapies in earlier lines, high adoption of newer therapies, mainly CAR-T cell therapies and bispecific antibodies, a rich emerging pipeline, and an expected increase in investment in R&D activities.

Hepatic Artery Infusion therapy delivers treatment directly tometastatic tumors in the liver, while minimizing the potential for systemic side effects

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With a high unmet need in these areas and limited competition, EMPAVELI's market is poised for steady growth.

New AI-Powered Support Assistant Helps Blood Cancer Patients Find Answers and Resources Faster

SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results.

PARIS und SAN FRANCISCO, 19. Mrz 2025 /PRNewswire/ -- Moon Surgical, ein franzsisch-amerikanischer Pionier auf dem Gebiet der chirurgischen Innovation, gab heute die Zulassung von ScoPilot durch die US-amerikanische Food and Drug Administration (FDA) bekannt. Ermglicht durch NVIDIA Holoscan, eine Echtzeit-Sensorplattform, die fr die Entwicklung und den Einsatz von auf knstlicher Intelligenz basierenden Anwendungen im Operationssaal konzipiert ist und lokal unter dem Maestro-System von Moon Surgical ausgefhrt wird. ScoPilot ist die erste KI-Anwendung, die intraoperativ auf jeder handelsblichen chirurgischen Roboterplattform mit Holoscan luft.

SAN FRANCISCO andSUZHOU, China, March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the FRUSICA-2 Phase 2/3 clinical trial evaluating sintilimab in combination with fruquintinib as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China has met its primary endpoint of progression free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR).